Design Therapeutics Inc (DSGN)

$3.88 -0.36 (-8.49%)
Market Cap 240.68M
Revenue (ttm) 0.00
Net Income (ttm) -49.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 137,700
Avg Vol 155,678
Day's Range N/A - N/A
Shares Out 56.76M
Stochastic %K 70%
Beta 1.82
Analysts Sell
Price Target $7.33

Latest News on DSGN

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Apr 21, 2025, 4:01 PM EDT - 4 days ago

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Apr 17, 2025, 8:00 AM EDT - 8 days ago

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 7:07 AM EDT - 6 weeks ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 7 weeks ago

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Nov 13, 2024, 8:00 AM EST - 5 months ago

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Nov 7, 2024, 4:01 PM EST - 6 months ago

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Aug 5, 2024, 8:00 AM EDT - 9 months ago

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

May 8, 2024, 4:05 PM EDT - 1 year ago

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 8:44 PM EDT - 1 year ago

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Mar 12, 2024, 6:30 AM EDT - 1 year ago

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Nov 13, 2023, 4:05 PM EST - 1 year ago

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Aug 15, 2023, 8:17 AM EDT - 1 year ago

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:05 PM EDT - 1 year ago

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

Aug 14, 2023, 4:01 PM EDT - 1 year ago

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

May 31, 2023, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

May 9, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Apr 24, 2023, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Feb 8, 2023, 6:30 AM EST - 2 years ago

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Dec 7, 2022, 4:01 PM EST - 2 years ago

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Nov 3, 2022, 4:05 PM EDT - 2 years ago

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Oct 17, 2022, 4:05 PM EDT - 2 years ago

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Sep 22, 2022, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Aug 8, 2022, 4:05 PM EDT - 2 years ago

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Aug 3, 2022, 6:30 AM EDT - 2 years ago

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Jun 1, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

May 9, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Mar 30, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Mar 10, 2022, 4:02 PM EST - 3 years ago

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Mar 9, 2022, 6:30 AM EST - 3 years ago

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Feb 28, 2022, 4:05 PM EST - 3 years ago

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Feb 10, 2022, 6:30 AM EST - 3 years ago

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Feb 1, 2022, 4:05 PM EST - 3 years ago

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Jan 19, 2022, 12:51 PM EST - 3 years ago

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Nov 9, 2021, 4:05 PM EST - 3 years ago

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

Sep 8, 2021, 6:30 AM EDT - 3 years ago

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Aug 9, 2021, 4:05 PM EDT - 4 years ago

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Jun 7, 2021, 4:10 PM EDT - 4 years ago

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Design Therapeutics Expands Board of Directors with Key Appointments

Jun 7, 2021, 4:05 PM EDT - 4 years ago

Design Therapeutics Expands Board of Directors with Key Appointments

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

May 10, 2021, 4:05 PM EDT - 4 years ago

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Mar 30, 2021, 4:05 PM EDT - 4 years ago

Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Design Therapeutics Announces Pricing of Initial Public Offering

Mar 25, 2021, 11:56 PM EDT - 4 years ago

Design Therapeutics Announces Pricing of Initial Public Offering

Design Therapeutics Seeks $228 Million In U.S. IPO

Mar 24, 2021, 9:00 AM EDT - 4 years ago

Design Therapeutics Seeks $228 Million In U.S. IPO

Design Therapeutics sets IPO terms, to be valued at more than $1 billion

Mar 22, 2021, 6:26 AM EDT - 4 years ago

Design Therapeutics sets IPO terms, to be valued at more than $1 billion